Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Donna Cassidy-Hanley
Advertisement
Donna Cassidy-Hanley is senior research associate at the department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY
Articles by Donna Cassidy-Hanley
Advertisement
Latest Updated Articles
An Alternative Platform for Rapid Production of Effective Subunit VaccinesPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
